- Home
- Publications
- Publication Search
- Publication Details
Title
IDO1 in cancer: a Gemini of immune checkpoints
Authors
Keywords
-
Journal
Cellular & Molecular Immunology
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-01-29
DOI
10.1038/cmi.2017.143
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum
- (2017) David M. Gershenson et al. JOURNAL OF CLINICAL ONCOLOGY
- Preparation and evaluation of L- and D-5-[ 18 F]fluorotryptophan as PET imaging probes for indoleamine and tryptophan 2,3-dioxygenases
- (2017) Tang Tang et al. NUCLEAR MEDICINE AND BIOLOGY
- Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells
- (2017) Yuying Liu et al. Nature Communications
- The Aryl Hydrocarbon Receptor Preferentially Marks and Promotes Gut Regulatory T Cells
- (2017) Jian Ye et al. Cell Reports
- Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis
- (2017) Rajeev K. Shrimali et al. Cancer Immunology Research
- STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
- (2016) Henrique Lemos et al. CANCER RESEARCH
- Improved Radiosynthesis and Biological Evaluations of L- and D-1-[18F]Fluoroethyl-Tryptophan for PET Imaging of IDO-Mediated Kynurenine Pathway of Tryptophan Metabolism
- (2016) Yangchun Xin et al. MOLECULAR IMAGING AND BIOLOGY
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Advanced age negatively impacts survival in an experimental brain tumor model
- (2016) Erik Ladomersky et al. NEUROSCIENCE LETTERS
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
- (2016) David H. Munn et al. TRENDS IN IMMUNOLOGY
- Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
- (2015) L. Zhai et al. CLINICAL CANCER RESEARCH
- Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
- (2015) Ute F. Röhrig et al. JOURNAL OF MEDICINAL CHEMISTRY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity
- (2015) Buvana Ravishankar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
- (2015) Rikke B. Holmgaard et al. Cell Reports
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
- (2015) Leticia Corrales et al. Cell Reports
- Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
- (2015) Nicolas van Baren et al. Frontiers in Immunology
- The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment
- (2015) M. D. Sharma et al. Science Advances
- Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
- (2015) Tara C Gangadhar et al. Journal for ImmunoTherapy of Cancer
- Abstract 1633: Novel specific- and dual- tryptophan-2,3-dioxygenase (TDO) and indoleamine-2,3-dioxygenase (IDO) inhibitors for tumor immunotherapy
- (2015) Mario R. Mautino et al. CANCER RESEARCH
- A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
- (2015) Hatem H. Soliman et al. Oncotarget
- Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1
- (2014) Georgios Pantouris et al. AMINO ACIDS
- CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
- (2014) R. Jitschin et al. BLOOD
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway
- (2014) Martina Ott et al. GLIA
- Marginal zone CD169+ macrophages coordinate apoptotic cell-driven cellular recruitment and tolerance
- (2014) B. Ravishankar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
- (2014) I. Theate et al. Cancer Immunology Research
- IDO2 in Immunomodulation and Autoimmune Disease
- (2014) George C. Prendergast et al. Frontiers in Immunology
- Trial watch: IDO inhibitors in cancer therapy
- (2014) Erika Vacchelli et al. OncoImmunology
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
- (2014) Minghui Li et al. Journal for ImmunoTherapy of Cancer
- Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer
- (2013) H. Zhang et al. BLOOD
- Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
- (2013) T. Z. Iversen et al. CLINICAL CANCER RESEARCH
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cutting Edge: DNA Sensing via the STING Adaptor in Myeloid Dendritic Cells Induces Potent Tolerogenic Responses
- (2013) L. Huang et al. JOURNAL OF IMMUNOLOGY
- Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
- (2013) J. Yu et al. JOURNAL OF IMMUNOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aire-Dependent Thymic Development of Tumor-Associated Regulatory T Cells
- (2013) S. Malchow et al. SCIENCE
- Targeting Tregs in Malignant Brain Cancer: Overcoming IDO
- (2013) Derek A. Wainwright et al. Frontiers in Immunology
- IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
- (2012) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Highlights on Molecular Mechanisms of MDSC-Mediated Immune Suppression: Paving the Way for New Working Hypotheses
- (2012) Samantha Solito et al. IMMUNOLOGICAL INVESTIGATIONS
- Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase
- (2012) B. Ravishankar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
- (2011) Maria T Pallotta et al. NATURE IMMUNOLOGY
- Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors
- (2011) Derek A. Wainwright et al. NEURO-ONCOLOGY
- The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
- (2011) Christiane A. Opitz et al. PLoS One
- Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
- (2010) X. Liu et al. BLOOD
- Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
- (2010) H. K. Koblish et al. MOLECULAR CANCER THERAPEUTICS
- Functional and phenotypic effects of AhR activation in inflammatory dendritic cells
- (2010) Jaishree Bankoti et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases
- (2009) Hajime J. Yuasa et al. COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY
- Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer
- (2009) Yuzo Suzuki et al. LUNG CANCER
- Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase
- (2008) Christoph F.A. Vogel et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
- (2008) Stefan Löb et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- High expression of indoleamine 2,3-dioxygenase gene in prostate cancer
- (2008) Chantal Feder-Mengus et al. EUROPEAN JOURNAL OF CANCER
- High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
- (2008) M. E.D. Chamuleau et al. HAEMATOLOGICA
- Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
- (2008) Ke Pan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now